Bayer buys women’s health company Kandy for $875m
The German drug and chemical giant will bolster its pharmaceuticals division before patents expire on some key products
11 August 2020 - 15:05
Munich — Bayer has struck an $875m deal to acquire British women’s health biotech Kandy Therapeutics, bolstering its pharmaceuticals division before patents expire on some key products.
The German drug and chemical company agreed to pay $425m upfront and potential milestone payments of $450m until the launch of Kandy’s experimental treatment for menopause symptoms...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.